Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
18792
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateNet Sales+72.6%
基準 10,886Target18,792million
Operating profit+60.4%
基準 2,026Target3,250million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
Key initiatives
01The strategy of pursuing highly achievable growth, with a particular focus on the US GI market, will continue under the plan for the fiscal year ending April 2027.
02The company plans to maintain conservative expectations for existing and new fields outside GI.
03The company will allow disciplined increases in selling, general and administrative expenses to strengthen its team structure and improve operational capabilities for continued growth.
04While prioritizing medium- to long-term growth over short-term profit generation, the company will continue to pursue the steady securing and expansion of profits after achieving profitability.
05Although no major clinical trials are planned in research and development, group resources will remain concentrated on accelerating the acquisition of new approvals in the US.
06Hemostasis in pediatric cardiac surgery
07Pain relief and hemostasis following pediatric and adult tonsil surgery
08Nasal hemostasis for Osler disease (HHT)
09Hemostasis after biopsy
10Hemostasis in surgery for benign prostatic hyperplasia
11Treatment of radiation proctitis
12Treatment of radiation cystitis
13Hemostasis in neurosurgery (new peptide)
14Mucosal wound healing
15Mucosal healing in inflammatory bowel disease
16Prevention of esophageal stenosis
17Prevention of dysphagia
18Oral mucositis
19Recovery of impaired cardiac function
20Bone-filling materials
21Slow release of existing drugs
22siRNA delivery for breast cancer
23miRNA delivery for malignant pleural mesothelioma
24Vaccine delivery
25Submucosal injection material for endoscopy (PureLift)
26Absorbable tissue spacer for radiation therapy
Plan assumptionsThe GI field is estimated to still have several-fold growth potential., No significant increase in sales resources is planned in Europe., Coverage of major hospitals in Japan is already high, leaving limited room for growth through new customer acquisition., In some regions of Japan, product use has been curtailed because reimbursement claims have been denied.
Segment targetSegment United States / Sales Target Fiscal year ending April 2027 8,590 / Fiscal year ending April 2028 10,750 / Fiscal year ending April 2029 12,666 / Operating profit target Not disclosed, Segment Europe / Sales Target Fiscal year ending April 2027 2,922 / Fiscal year ending April 2028 3,408 / Fiscal year ending April 2029 4,101 / Operating profit target Not disclosed, Segment Japan / Sales Target Fiscal year ending April 2027 1,100 / Fiscal year ending April 2028 1,100 / Fiscal year ending April 2029 1,100 / Operating profit target Not disclosed, Segment Other / Sales Target Fiscal year ending April 2027 810 / Fiscal year ending April 2028 885 / Fiscal year ending April 2029 925 / Operating profit target Not disclosed
Size of the Target MarketMarket Addressable market for hemostatic materials for gastrointestinal endoscopy / Scale ¥41.9 billion / Growth rate Not disclosed / Source Company estimate. Calculated from the number of cases and average selling prices in the five major European countries, then extrapolated worldwide based on the ratio of 2018 GDP., Market Potential market for hemostatic materials for gastrointestinal endoscopy / Scale ¥104.3 billion / Growth rate Not disclosed / Source Company estimate. Calculated from the estimated number of cases and average selling prices in the five major European countries, then extrapolated worldwide based on the ratio of 2018 GDP., Market Overall addressable market for hemostatic materials / Scale ¥380 billion / Growth rate Not disclosed / Source 2020, MarketsandMarkets, Hemostats Market by Type, Application, Formulation - Global Forecast to 2026, Market Anti-adhesion materials for otolaryngology / Scale Approximately ¥50 billion / Growth rate Not disclosed / Source Company estimate based on global market size and the number of cases., Market Global addressable market for anti-adhesion materials / Scale Approximately ¥100 billion / Growth rate Not disclosed / Source Company estimate based on Adhesion Barrier Market by Product ... - Global Forecast to 2025., Market Regenerative medicine products / Scale ¥1 trillion in 2020, ¥12 trillion in 2030, ¥38 trillion in 2050 / Growth rate Average annual growth rate of 28.21% from 2020 to 2030, 5.93% from 2030 to 2050, and approximately 30% annually over the next 10 years / Source Bioindustry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry, document dated 2 March 2020, Market Inflammatory bowel disease (IBD) / Scale Approximately ¥3 trillion / Growth rate Not disclosed / Source Pharmaceutical, Inflammatory Bowel Disease Treatment Market published in May 2022, Market Radiation proctitis / Scale Several tens of billions of yen / Growth rate Not disclosed / Source Not disclosed, Market Nucleic acid therapeutics / Scale ¥0.2 trillion in 2018, ¥1.3 trillion in 2025, ¥2.0 trillion in 2030 / Growth rate Not disclosed / Source Seed Planning Corporation, 2019 edition of Current Status and Future Prospects of Nucleic Acid Therapeutics Development Worldwide
Risks identified by the company
Legal regulations
Earnings Plan
Sales structure
Manufacturing and Inventory
Product Liability
Patents
Financial position
Reason for revision or withdrawal
No revision or withdrawal is disclosed.
| Item | Details |
|---|---|
| Plan name | Medium-Term Management Plan for the Fiscal Year Ending April 2027 |
| Plan period | Fiscal years ending April 2027 to April 2029 |
| Progress against the plan | Annual update |
| Sales Target | Actual for the fiscal year ended April 2026: 10,886 → Target for the fiscal year ending April 2029: 18,792 |
| Operating profit target | Actual for the fiscal year ended April 2026: 1,335 → Target for the fiscal year ending April 2029: 3,250 |
| Segment target | Segment United States / Sales Target Fiscal year ending April 2027 8,590 / Fiscal year ending April 2028 10,750 / Fiscal year ending April 2029 12,666 / Operating profit target Not disclosed, Segment Europe / Sales Target Fiscal year ending April 2027 2,922 / Fiscal year ending April 2028 3,408 / Fiscal year ending April 2029 4,101 / Operating profit target Not disclosed, Segment Japan / Sales Target Fiscal year ending April 2027 1,100 / Fiscal year ending April 2028 1,100 / Fiscal year ending April 2029 1,100 / Operating profit target Not disclosed, Segment Other / Sales Target Fiscal year ending April 2027 810 / Fiscal year ending April 2028 885 / Fiscal year ending April 2029 925 / Operating profit target Not disclosed |
| Plan assumptions | The GI field is estimated to still have several-fold growth potential., No significant increase in sales resources is planned in Europe., Coverage of major hospitals in Japan is already high, leaving limited room for growth through new customer acquisition., In some regions of Japan, product use has been curtailed because reimbursement claims have been denied. |
| Key initiatives | The strategy of pursuing highly achievable growth, with a particular focus on the US GI market, will continue under the plan for the fiscal year ending April 2027., The company plans to maintain conservative expectations for existing and new fields outside GI., The company will allow disciplined increases in selling, general and administrative expenses to strengthen its team structure and improve operational capabilities for continued growth., While prioritizing medium- to long-term growth over short-term profit generation, the company will continue to pursue the steady securing and expansion of profits after achieving profitability., Although no major clinical trials are planned in research and development, group resources will remain concentrated on accelerating the acquisition of new approvals in the US., Hemostasis in pediatric cardiac surgery, Pain relief and hemostasis following pediatric and adult tonsil surgery, Nasal hemostasis for Osler disease (HHT), Hemostasis after biopsy, Hemostasis in surgery for benign prostatic hyperplasia, Treatment of radiation proctitis, Treatment of radiation cystitis, Hemostasis in neurosurgery (new peptide), Mucosal wound healing, Mucosal healing in inflammatory bowel disease, Prevention of esophageal stenosis, Prevention of dysphagia, Oral mucositis, Recovery of impaired cardiac function, Bone-filling materials, Slow release of existing drugs, siRNA delivery for breast cancer, miRNA delivery for malignant pleural mesothelioma, Vaccine delivery, Submucosal injection material for endoscopy (PureLift), Absorbable tissue spacer for radiation therapy |
| Reason for revision or withdrawal | No revision or withdrawal is disclosed. |
| Size of the Target Market | Market Addressable market for hemostatic materials for gastrointestinal endoscopy / Scale ¥41.9 billion / Growth rate Not disclosed / Source Company estimate. Calculated from the number of cases and average selling prices in the five major European countries, then extrapolated worldwide based on the ratio of 2018 GDP., Market Potential market for hemostatic materials for gastrointestinal endoscopy / Scale ¥104.3 billion / Growth rate Not disclosed / Source Company estimate. Calculated from the estimated number of cases and average selling prices in the five major European countries, then extrapolated worldwide based on the ratio of 2018 GDP., Market Overall addressable market for hemostatic materials / Scale ¥380 billion / Growth rate Not disclosed / Source 2020, MarketsandMarkets, Hemostats Market by Type, Application, Formulation - Global Forecast to 2026, Market Anti-adhesion materials for otolaryngology / Scale Approximately ¥50 billion / Growth rate Not disclosed / Source Company estimate based on global market size and the number of cases., Market Global addressable market for anti-adhesion materials / Scale Approximately ¥100 billion / Growth rate Not disclosed / Source Company estimate based on Adhesion Barrier Market by Product ... - Global Forecast to 2025., Market Regenerative medicine products / Scale ¥1 trillion in 2020, ¥12 trillion in 2030, ¥38 trillion in 2050 / Growth rate Average annual growth rate of 28.21% from 2020 to 2030, 5.93% from 2030 to 2050, and approximately 30% annually over the next 10 years / Source Bioindustry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry, document dated 2 March 2020, Market Inflammatory bowel disease (IBD) / Scale Approximately ¥3 trillion / Growth rate Not disclosed / Source Pharmaceutical, Inflammatory Bowel Disease Treatment Market published in May 2022, Market Radiation proctitis / Scale Several tens of billions of yen / Growth rate Not disclosed / Source Not disclosed, Market Nucleic acid therapeutics / Scale ¥0.2 trillion in 2018, ¥1.3 trillion in 2025, ¥2.0 trillion in 2030 / Growth rate Not disclosed / Source Seed Planning Corporation, 2019 edition of Current Status and Future Prospects of Nucleic Acid Therapeutics Development Worldwide |
| Risks identified | Legal regulations, Earnings Plan, Sales structure, Manufacturing and Inventory, Product Liability, Patents, Financial position |
| Publication date | July 2026 |
Items this document does not state (13)
Operating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorNon-financial targetsResults under the previous planDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company will continue pursuing a strategy aimed at highly achievable growth, with a particular focus on the US GI market, while maintaining conservative expectations for existing and new fields outside GI. It will allow disciplined increases in selling, general and administrative expenses to strengthen its team structure and operational capabilities for sustained growth. While prioritizing medium- to long-term growth over short-term profit generation, it will also seek to secure and expand profits after achieving profitability. In research and development, the company does not plan any major clinical trials and will concentrate group resources on obtaining new approvals in the US.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.